marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2023-Q2
added 08-03-2023
Paratek Pharmaceuticals Balance Sheet 2011-2024 | PRTK
Annual Balance Sheet Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
223 M | 174 M | 147 M | 272 M | 385 M | 140 M | 61.1 M | -112 M | -91.3 M | -9.94 M | -39.4 M | -10.7 M |
Long Term Debt |
257 M | 254 M | 250 M | 261 M | 229 M | 59.2 M | 39 M | 19.6 M | - | - | - | - |
Long Term Debt Current |
500 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 255 M | 267 M | 235 M | 64.4 M | 43.7 M | 24.2 M | 11 M | - | - | 60 K |
Total Current Liabilities |
37.4 M | 31.3 M | 24 M | 24.2 M | 17.7 M | 16.8 M | 20.4 M | 20.5 M | 3.74 M | 34.8 M | 2.66 M | 3.34 M |
Total Liabilities |
344 M | 312 M | 279 M | 291 M | 253 M | 81.2 M | 64.1 M | 44.7 M | 14.7 M | 1.93 M | 2.66 M | 3.4 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-930 M | -867 M | -808 M | -711 M | -582 M | -470 M | -380 M | -269 M | -198 M | -140 M | -112 M | -100 M |
Total Assets |
173 M | 184 M | 177 M | 251 M | 300 M | 164 M | 136 M | 146 M | 110 M | 73.7 M | 98.1 M | 69.2 M |
Cash and Cash Equivalents |
34.2 M | 80.4 M | 105 M | 102 M | 47 M | 35.4 M | 53 M | 131 M | 95.9 M | 1.21 M | 39.4 M | 10.7 M |
Book Value |
-171 M | -128 M | -102 M | -39.6 M | 47.6 M | 82.5 M | 71.6 M | 101 M | 95.2 M | 71.7 M | 95.4 M | 65.8 M |
Total Shareholders Equity |
-171 M | -128 M | -102 M | -39.6 M | 47.6 M | 82.5 M | 71.6 M | 101 M | 95.2 M | -114 M | -113 M | 65.8 M |
All numbers in USD currency
Quarterly Balance Sheet Paratek Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
94.3 M | 258 M | 257 M | 258 M | - | 256 M | 254 M | 253 M | 253 M | 251 M | 250 M | 250 M | 250 M | 250 M | 261 M | 261 M | 261 M | 261 M | 229 M | 229 M | 229 M | 229 M | 59.2 M | 59.2 M | 59.2 M | 59.2 M | 39 M | 39 M | 39 M | 39 M | 19.6 M | 19.6 M | 19.6 M | 19.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
347 M | 340 M | 344 M | 323 M | - | 310 M | 312 M | 287 M | 279 M | 278 M | 279 M | 279 M | 279 M | 279 M | 291 M | 291 M | 291 M | 291 M | 253 M | 253 M | 253 M | 253 M | 81.2 M | 81.2 M | 81.2 M | 81.2 M | 64.1 M | 64.1 M | 64.1 M | 64.1 M | 44.7 M | 44.7 M | 44.7 M | 44.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 35.1 M | - | - | - | 2.66 M | 3.37 M | 3.12 M | 2.64 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 191 K | - | - | - | - | - | - | - | - | 417 K | 1.04 M | - |
Retained Earnings |
-965 M | -951 M | -930 M | -923 M | - | -885 M | -867 M | -835 M | -816 M | -826 M | -808 M | -808 M | -808 M | -808 M | -711 M | -711 M | -711 M | -711 M | -582 M | -582 M | -582 M | -582 M | -470 M | -470 M | -470 M | -470 M | -380 M | -380 M | -380 M | -380 M | -269 M | -269 M | -269 M | -269 M | -198 M | -198 M | -198 M | -198 M | -180 M | -140 M | -140 M | -140 M | -112 M | -112 M | -112 M | -112 M | -100 M | -100 M | -100 M | -100 M |
Total Assets |
146 M | 151 M | 173 M | 157 M | - | 170 M | 184 M | 182 M | 180 M | 159 M | 177 M | 177 M | 177 M | 177 M | 251 M | 251 M | 251 M | 251 M | 300 M | 300 M | 300 M | 300 M | 164 M | 164 M | 164 M | 164 M | 136 M | 136 M | 136 M | 136 M | 146 M | 146 M | 146 M | 146 M | 110 M | 110 M | 110 M | 110 M | 1.28 M | 73.7 M | 73.7 M | 73.7 M | 98.1 M | 98.1 M | 98.1 M | 98.1 M | 69.2 M | 69.2 M | 69.2 M | 69.2 M |
Cash and Cash Equivalents |
42.7 M | 45 M | 34.2 M | 27.1 M | 39.5 M | 49 M | 80.4 M | 111 M | 75.3 M | 103 M | 105 M | 105 M | 105 M | 105 M | 102 M | 102 M | 102 M | 102 M | 47 M | 47 M | 47 M | 47 M | 35.4 M | 35.4 M | 35.4 M | 35.4 M | 53 M | 53 M | 53 M | 53 M | 131 M | 131 M | 131 M | 131 M | 95.9 M | 95.9 M | 95.9 M | 21.4 M | 1.21 M | 9.94 M | 9.94 M | 9.94 M | 1.02 M | 39.4 M | 39.4 M | 39.4 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M |
Book Value |
-201 M | -189 M | -171 M | -166 M | - | -140 M | -128 M | -105 M | -99.3 M | -119 M | -102 M | -102 M | -102 M | -102 M | -39.6 M | -39.6 M | -39.6 M | -39.6 M | 47.6 M | 47.6 M | 47.6 M | 47.6 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | 71.6 M | 71.6 M | 71.6 M | 71.6 M | 101 M | 101 M | 101 M | 101 M | 95.2 M | 95.2 M | 95.2 M | 95.2 M | -33.8 M | 73.7 M | 73.7 M | 73.7 M | 95.4 M | 94.7 M | 94.9 M | 95.4 M | 65.8 M | 65.8 M | 65.8 M | 65.8 M |
Total Shareholders Equity |
-201 M | -189 M | -171 M | -166 M | -149 M | -140 M | -128 M | -105 M | -99.3 M | -119 M | -102 M | -102 M | -102 M | -102 M | -39.6 M | -39.6 M | -39.6 M | -39.6 M | 47.6 M | 47.6 M | 47.6 M | 47.6 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | 71.6 M | 71.6 M | 71.6 M | 71.6 M | 101 M | 101 M | 101 M | 101 M | 95.2 M | 95.2 M | 95.2 M | 95.2 M | -114 M | 71.7 M | 71.7 M | 71.7 M | -113 M | 95.4 M | 95.4 M | 95.4 M | 65.8 M | 65.8 M | 65.8 M | 65.8 M |
All numbers in USD currency